In breast cancer, however, most studies conducted so far could not identify benefits from applying EGFR targeted treatments and one of the hypotheses explaining the disappointing results is the heterogeneous nature of breast cancer and lack of valid predictive biomarkers to enable selection of patients who are most likely to respond to treatment4–6. This evidence concerns the gene EGFR and breast carcinoma.